Key result
WHO performance status was the strongest independent predictor of major bleeding during heparin or LMWH treatment, with grade 4 patients having an eightfold increased risk compared to grade 1.
Why the study?
What are the independent risk factors for bleeding in patients treated with heparin or LMWH for acute venous thromboembolism?
Population
194 patients with acute venous thromboembolism
Design
RCT, double-blind
Authors
Loading...
Poor performance status markedly raises major bleeding risk on heparin/LMWH for VTE; extends risk stratification to inform individualized therapy decisions.
RCT (n=194)
Double-blind
What are the independent risk factors for bleeding in patients treated with heparin or LMWH for acute venous thromboembolism?
WHO performance status, history of bleeding tendency, recent trauma or surgery, body surface area, and high anti-Xa levels/drug doses are key independent risk factors for bleeding during heparin or LMWH therapy for acute VTE.
Nieuwenhuis et al. (1991) conducted an RCT in acute venous thromboembolism (n=194). Low molecular weight heparin (Fragmin) vs. Heparin was evaluated on Bleeding. WHO performance status was the strongest independent predictor of major bleeding during heparin or LMWH treatment, with grade 4 patients having an eightfold increased risk compared to grade 1.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: